Clinical Trials Directory

Trials / Unknown

UnknownNCT01286727

Study to Improve Renal Function After Kidney Transplantation

Multicenter Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation and at Risk for Dialysis

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Angion Biomedica Corp · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of the study is to evaluate the safety and activity of a investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms of significant renal injury and are at risk for dialysis.

Detailed description

Delayed graft function (DGF) is generally defined as the need for dialysis during the first 7 days after transplantation although the definition can also include failure to improve preexisting renal function. DGF is an important problem in renal allograft transplantation that affects approximately 25% of transplanted cadaveric kidneys. It has generally been observed that delayed graft function has been associated with reduced graft survival. In addition to an association of DGF with graft loss, DGF imposes an economic burden due to prolonged hospitalization and dialysis. The strongest association with occurrence of DGF is ischemia around the time of transplantation. Aside from approaches to minimize ischemia time and use of antibody induction, there are no good specific therapeutic options to prevent or treat delayed graft function. This study is designed to evaluate the safety and activity of an investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms of significant renal injury and are at risk for dialysis.

Conditions

Interventions

TypeNameDescription
DRUGBB3intravenous drug

Timeline

Start date
2010-02-01
Primary completion
2015-01-01
Completion
2016-02-01
First posted
2011-01-31
Last updated
2015-05-05

Locations

6 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01286727. Inclusion in this directory is not an endorsement.